Cargando…

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Detalles Bibliográficos
Autores principales:	Pires, Antonio, Goyal, Kavitha, Greenspan, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993843/ https://www.ncbi.nlm.nih.gov/pubmed/29785562 http://dx.doi.org/10.1007/s40265-018-0918-2

Ejemplares similares

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Cohen, Hillel P., et al.
Publicado: (2018)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”
por: Strowitzki, Thomas, et al.
Publicado: (2016)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis
por: Herndon, Thomas M., et al.
Publicado: (2023)

Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015)

Comment on Models in Medicine
por: Ravindranath, Thyyar Madabushi
Publicado: (2017)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Comment on “A Systematic Literature Review of Three Modalities in Technologically Assisted TKA”
por: Vaishya, Raju, et al.
Publicado: (2016)

Author reply to comments
por: Bhalla, Ashu Seith, et al.
Publicado: (2015)

Comment on “Chinese Herbal Medicine for Osteoporosis: A Systematic Review of Randomized Controlled Trails”
por: Lai, Qi-wei
Publicado: (2013)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

Biosimilar insulins: An unavoidable option in South-East Asia
por: Kaduskar, Prashant Ulhas
Publicado: (2016)

Response to comments on: Retinal vein occlusion in COVID-19: A novel entity
por: Sheth, Jay U, et al.
Publicado: (2021)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
por: Ascef, Bruna O., et al.
Publicado: (2021)

Clinical and conceptual comments on “Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis”
por: Jayaraj, Rama, et al.
Publicado: (2020)

Considerations for the US health-system pharmacist in a world of biosimilars
por: Zlatkus, Andrea, et al.
Publicado: (2020)

Caffeine for the prevention of postoperative nausea and vomiting — Few comments
por: Vaidya, Shriram, et al.
Publicado: (2014)

Comment on: Refractive outcome analyses in myopes
por: Pitsas, Christos, et al.
Publicado: (2015)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Response comment on: Retinal manifestations in patients following COVID-19 infection
por: Goyal, Mallika, et al.
Publicado: (2021)

Author’s reply to ‘Rickettsia retinitis cases in India: a few comments’
por: Kawali, Ankush A., et al.
Publicado: (2016)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Comment on the maternal and neonatal outcomes of gestational diabetes
por: Majella, Marie Gilbert, et al.
Publicado: (2016)

Response to comment on: Comment on: Clinical presentations and comparative outcomes of primary versus deferred intraocular lens explantation in delayed-onset endophthalmitis
por: Dave, Vivek Pravin
Publicado: (2020)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6raqq4a27rbl5tfpbvf30ck33j